Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 5 Distribution of patients with and without programmed cell death protein 1 ligand 1-positive fibroblastic stroma, n (%)

Breast cancer characteristics	PDCD1 LG1+ fibroblastic stroma		P value χ² tests
	Absent	Present
T stage
Т in situ	4 (100)	0 (0)	0.026
Т1в	6 (54.5)	5 (45.5)
Т1с	59 (66.3)	30 (33.7)
Т2	38 (86.4)	6 (13.6)
N stage
N0	60 (74.1)	21 (25.9)	0.73
N1	33 (70.2)	14 (29.8)
N2	12 (75.0)	4 (25.0)
N3	2 (50.0)	2 (50.0)
Tumor grade (G)
G1	10 (62.5)	6 (37.5)	0.61
G2	66 (72.5)	25 (27.5)
G3	31 (75.6)	10 (24.4)
Lymphovascular invasion
No	63 (75.0)	21 (25.0)	0.39
Yes	44 (68.8)	20 (31.2)
Perineural invasion
No	80 (69.6)	35 (30.4)	0.16
Yes	27 (81.8)	6 (18.2)
ER status
Negative	8 (50.0)	8 (50.0)	0.03
Positive	99 (75.0)	33 (25.0)
PR status
Negative	31 (75.6)	10 (24.4)	0.57
Positive	76 (71.0)	31 (29.0)
HER2 status
HER2 -	99 (77.3)	29 (22.6)	0.0005
HER2+	8 (40.0)	12 (60.0)
Molecular biological subtype
Luminal A	44 (78.6)	12 (21.4)	0.004
Luminal B HER2-	52 (78.8)	14 (21.2)
Luminal B HER2+	3 (30.0)	7 (70.0)
Non-luminal HER2+	5 (50.0)	5 (50.0)
TNBC	3 (50.0)	3 (50.0)

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple-negative breast cancer; PDCD1 LG1: Programmed cell death protein 1 ligand 1.